ClinicalTrials.gg
Not yet recruitingNCT07754045Updated Aug 10, 2026

Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults

A Phase 2 interventional study of LUM-201 and Placebo in Obesity & Overweight, sponsored by Lumos Pharma. Not yet recruiting. Open to participants aged 60 Years to 84 Years. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Lumos Pharma · Phase 2, Interventional, and Treatment

Phase
Phase 2
Study type
Interventional
Enrollment
202
Allocation
Randomized
Ages
60 Years to 84 Years
Sex
All
01

Study summary

This is a phase 2 randomized, double-blind, placebo-controlled, multi-center study evaluating the efficacy and safety of LUM-201 plus Semaglutide versus Semaglutide plus placebo in obese adults with body mass index between 30 and 45 kg/m\^2, between the ages of 60 and 85 years that have mild functional impairment.

02

Conditions studied

  • Obesity & Overweight
03

In context

Obesity

11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.

This study's planned enrollment of 202 is above the median of 67 across 9,006 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Lumos Pharma is the lead sponsor of 8 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be willing to provide written to participate in this study.
  • Males or females, aged ≥ 60 to \< 85 years.
  • Have a ≥ 30 kg/m2.
  • SPPB score at the screening visit ≥ 7 to ≤ 9.
  • Have a history of ≥ 1 self-reported unsuccessful dietary effort to lose weight.
  • Female participants must be , confirmed by an follicle stimulating hormone (FSH) level ≥ 25 IU/L.
  • Male participants must be able to comply with requirements.
  • Must agree to refrain from any reconstructive and/or cosmetic surgery and/or non-invasive cosmetic procedure that may affect body weight during the study such as mammoplasty, lipoplasty, non-invasive adipose and/or cellulite treatment devices.
  • Must refrain from scheduling any elective surgery and/or other invasive or non-invasive procedures during the study unless medically warranted.

Exclusion criteria

Exclusion Criteria:

  • Have Type 1 diabetes mellitus (T1DM) or Type 2 diabetes mellitus (T2DM).
  • Have laboratory evidence diagnostic of diabetes mellitus during screening.
  • Have history of diabetic ketoacidosis or hyperosmolar state/coma within 6 months prior to screening.
  • Have a history of severe hypoglycemia.
  • Have a > 45 kg/m2 or weight > 159 kg (350 lbs.).
  • Have a self-reported change in body weight > 5 kg (11 lbs.) within 3 months prior to screening.
  • Have received prior exposure to a GLP-1 receptor agonist (including dual GLP-1/ GIP receptor agonists]) within 180 days before screening, any other anti-obesity medication, glucose-lowering agent (non-GLP-1), or glucose lowering supplements such as berberine, etc. within 90 days before screening.
  • Have any other condition not listed in this section (for example, or intolerance) that is a to GLP-1 receptor agonist or dual GLP-1/GIP receptor agonist.
  • Have serum calcitonin concentration > 35 pg/mL at screening.
  • Have a history of prior or planned surgical treatment for obesity.
  • Have uncontrolled hypertension with systolic blood pressure (SBP) ≥ 150 mm Hg and/or diastolic blood pressure (DBP) ≥ 95 mm Hg.
  • Mean (Fridericia [QTcF=QT/RR1/3]) interval > 450 ms (male) or > 470 ms (female) on triplicate ECGs.
  • Have fasting triglyceride > 500 mg/dL.
  • Have any of the following within last 6 months prior to screening: Functional Classification I-IV heart failure, myocardial infarction, angina, coronary artery bypass graft, percutaneous coronary intervention, , stroke, or decompensated congestive heart failure.
  • Have an estimated (eGFR) \< 60 mL/min/1.73 m2.
  • Have a known gastric emptying abnormality.
  • Have a history of chronic or acute pancreatitis, or severe gastroesophageal reflux disease and symptomatic cholelithiasis with intact gallbladder.
  • Have serum lipase and/or amylase above 1.5 × the (ULN).
  • Have a history of hepatic disorders including cirrhosis or other hepatic disorder other than metabolic-associated fatty liver disease (MAFLD), or nonalcoholic fatty liver disease.
  • Have active or C virus at screening. Have known positive history of . Have an active Coronavirus Disease 2019 at screening.
  • Have an impaired liver function, defined as screening (AST) > 2.5 × ULN, or alanine aminotransferase > 2.5 × ULN, or total level > 1.2 × ULN (except for cases of known Gilbert's Syndrome).
  • Alkaline phosphatase (ALP) level > 1.5 × ULN.
  • Have untreated or uncontrolled hypothyroidism or hyperthyroidism.
  • Have obesity induced by other endocrinologic disorders.
  • Have a history of significant active or unstable Major Depressive Disorder (MDD) or other severe psychiatric disorder within the last 2 years.
  • Have any lifetime history of a suicide attempt.
  • Have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
  • Have a history of an active or untreated or are in remission from a clinically significant malignancy (other than basal- or squamous-cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) within the past 5 years prior to screening.
  • Have had a transplanted organ (corneal transplants [keratoplasty] allowed) or awaiting an organ transplant.
  • Have any hematological condition that may interfere with measurement (for example, hemolytic anemias, sickle cell disease).
  • Are receiving or have received within 3 months prior to screening chronic (> 2 weeks or 14 days) systemic therapy or have evidence of a significant active abnormality that has required treatment within the last 3 months.
  • Have current or recent treatment with medications and/or supplements that may cause significant weight gain.
  • Currently receiving or planning to initiate during the study any muscle toning or body contouring treatments such as high-intensity focused electromagnetic therapy, or neurotoxin injections targeting large muscle groups (for example, trapezius, gastrocnemius) for slimming or relaxation purposes.
  • Have taken within 3 months prior to randomization, medications (prescribed or over-the counter) or alternative remedies intended to promote weight loss.
  • Have started implantable or injectable (such as Depo-Provera®) within 6 months prior to screening.
  • Documented moderate to severe obstructive sleep apnea (unless controlled by medically prescribed intervention for at least 3 months prior to screening).
  • Prior treatment with growth factors including, but not limited to, GH, IGF-1, and GH secretagogues.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
202 participants (estimated)

Study arms

  • Experimental
    LUM-201 plus Semaglutide

    Drug: LUM-201 · Drug: Semagludtide

  • Placebo comparator
    Semaglutide plus placebo

    Drug: Placebo · Drug: Semagludtide

Interventions

  • Daily (AM) oral Tablet at 25 mg

  • DrugPlacebo

    Daily (AM) oral Tablet

  • Daily (AM) oral Tablet

06

What researchers measure

Primary outcomes

  1. Proportion of participants with Short Physical Performance Battery (SPPB) score ≤ 7 at Week 26.

    Time frame: From Day 1 to week 26

Secondary outcomes

  1. Change from baseline to Week 26 in total body fat mass (kg) measured by dual-energy X-ray absorptiometry (DEXA).

    Time frame: Day 1 to week 26.

  2. Change from baseline to Week 26 in total lean mass (kg) measured by dual-energy X-ray absorptiometry (DEXA).

    Time frame: Day 1 to week 26.

  3. Change from baseline to Week 26 in fat-free mass (kg) measured by dual-energy X-ray absorptiometry (DEXA).

    Time frame: Day 1 to week 26.

  4. Change from baseline to Week 26 in body weight (kg).

    Time frame: Day 1 to week 26.

  5. Change from baseline to Week 26 in waist:hip ratio.

    Time frame: Day 1 to week 26.

  6. Change from baseline to Week 26 in waist:height ratio.

    Time frame: Day 1 to week 26.

  7. Assess safety and tolerability of LUM-201 in the presence of semaglutide.

    Incidence of treatment emergent adverse events, adverse events (AEs), and serious adverse events (SAEs). Clinically significant changes from Baseline to Week 26 in safety evaluations.

    Time frame: Day 1 to week 26

  8. Change from Baseline to Week 26 in Individual Short Physical Performance Battery (SPPB) Test.

    Time frame: Day 1 to week 26

  9. Difference in proportions of participants achieving a clinically meaningful positive Short Physical Performance Battery (SPPB) change (1-point).

    Time frame: Day 1 to week 26

  10. Change from Baseline to Week 26 in mean Short Physical Performance Battery (SPPB).

    Time frame: Day 1 to week 26

  11. Change from Baseline to Week 26 in Stair Climb (Power/Time).

    Time frame: Day 1 to week 26

  12. Change from Baseline to Week 26 in 6 Minute Walk Test (6MWT).

    Time frame: Day 1 to week 26

  13. Change from Baseline to Week 26 in Grip Strength in kg using a hand dynamometer.

    Time frame: Day 1 to week 26

  14. Change from Baseline to Week 26 in Knee extension.

    Time frame: Day 1 to week 26

  15. Change from Baseline to Week 26 in Patient reported Outcome (PRO) questionnaire Short Form-36 (SF-36) score.

    Time frame: Day 1 to week 26

  16. Change from Baseline to Week 26 in Patient reported Outcome (PRO) questionnaire Impact of Weight on Quality of Life-Lite (IWQoL-Lite) score.

    Time frame: Day 1 to week 26

  17. Change from Baseline to Week 26 in Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue measurements score.

    Time frame: Day 1 to week 26

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2027; primary completion for Feb 2028, 12 months later.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's planned 12 months is close to that.

Counting every sponsor, half of 308 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2026
First posted
Aug 10, 2026
StartEst.
Feb 15, 2027
Primary completionEst.
Feb 15, 2028
CompletionEst.
Feb 15, 2028
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07754045
Lead sponsor
Lumos Pharma
Responsible party
Sponsor
First posted
Aug 10, 2026
Start date
Feb 15, 2027 (estimated)
Primary completion
Feb 15, 2028 (estimated)
Completion
Feb 15, 2028 (estimated)
Last update
Aug 10, 2026

Study contacts

Lumos Pharma
Contact
clinical.trials@lumos-pharma.com
515-296-5555

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibutamoren

Start the discussion